|
| related topics |
| {product, candidate, development} |
| {product, market, service} |
| {regulation, change, law} |
| {property, intellectual, protect} |
| {system, service, information} |
| {product, liability, claim} |
| {debt, indebtedness, cash} |
| {regulation, government, change} |
| {financial, litigation, operation} |
|
|
MSD s success is dependent on the successful development and marketing of new products, which are subject to substantial risks.
MSD s products, including products in development, can not be marketed unless MSD obtains and maintains regulatory approval.
MSD is dependent on its patent rights, and if its patent rights are invalidated or circumvented, its business would be adversely affected.
MSD faces intense competition from lower-cost generic products.
MSD faces intense competition from new products.
MSD faces pricing pressure with respect to its products.
The health care industry will continue to be subject to increasing regulation and political action.
MSD is experiencing difficulties and delays in the manufacturing of certain of its products.
MSD faces significant litigation related to
and the ENHANCE and SEAS clinical trials have had an adverse effect on sales of
in the United States and results from ongoing trials could have an adverse effect on such sales.
Pharmaceutical products can develop unexpected safety or efficacy concerns.
Changes in laws and regulations could adversely affect MSD s business.
Reliance on third party relationships and outsourcing arrangements could adversely affect MSD s business.
MSD is increasingly dependent on sophisticated information technology and infrastructure.
Developments following regulatory approval may adversely affect sales of MSD s products.
MSD is subject to evolving and complex tax laws, which may result in additional liabilities that may affect results of operations.
MSD s debt obligations incurred to finance the Merger could adversely affect its business.
Product liability insurance for products may be limited, cost prohibitive or unavailable.
Cautionary Factors that May Affect Future Results
Full 10-K form ▸
|
|
| related documents |
| 895051--3/13/2009--ENTREMED_INC |
| 805326--3/25/2010--EMISPHERE_TECHNOLOGIES_INC |
| 805326--3/16/2009--EMISPHERE_TECHNOLOGIES_INC |
| 805326--3/6/2007--EMISPHERE_TECHNOLOGIES_INC |
| 1005201--3/16/2006--DEPOMED_INC |
| 819050--2/23/2007--VICAL_INC |
| 818033--3/31/2006--AP_PHARMA_INC_/DE/ |
| 882796--3/9/2010--BIOCRYST_PHARMACEUTICALS_INC |
| 1066833--3/15/2006--DOV_PHARMACEUTICAL_INC |
| 1140028--3/16/2006--Hana_Biosciences_Inc |
| 887151--3/13/2006--ORTHOLOGIC_CORP |
| 819050--3/10/2006--VICAL_INC |
| 1029142--3/16/2006--DYNAVAX_TECHNOLOGIES_CORP |
| 799698--4/3/2006--CYTRX_CORP |
| 1003124--2/26/2010--PHARMACEUTICAL_PRODUCT_DEVELOPMENT_INC |
| 1123979--2/4/2010--SENOMYX_INC |
| 1033025--3/17/2006--PRAECIS_PHARMACEUTICALS_INC |
| 1029142--3/16/2007--DYNAVAX_TECHNOLOGIES_CORP |
| 1123979--2/12/2009--SENOMYX_INC |
| 819050--3/3/2008--VICAL_INC |
| 819050--3/3/2009--VICAL_INC |
| 819050--2/25/2010--VICAL_INC |
| 824068--3/14/2008--ATS_MEDICAL_INC |
| 1093691--3/16/2009--PLUG_POWER_INC |
| 1396238--3/31/2010--IRIS_BIOTECHNOLOGIES_INC |
| 1396238--3/31/2009--IRIS_BIOTECHNOLOGIES_INC |
| 907562--3/4/2009--DYAX_CORP |
| 730272--6/9/2006--REPLIGEN_CORP |
| 1162192--3/31/2009--AVALON_PHARMACEUTICALS_INC |
| 882796--3/6/2009--BIOCRYST_PHARMACEUTICALS_INC |
|